Effects of Pentoxifylline on Amikacin-Induced Nephrotoxicity in Rats

REFERENCES

• Begg EJ, Barclay ML. Aminoglycosides 50 years on. Br J Clin Pharmacol. 1995; 39: 597–603
   PubMed Web of Science ®Google Scholar
• Kaynar K, Gul S, Ersoz S, Ozdemir F, Ulusoy H, Ulusoy S. Amikacin-induced nephropathy: Is there any protective way?. Ren Fail. 2007; 29(1)23–27
   PubMed Web of Science ®Google Scholar
• Parlakpinar H, Ozer MK, Ucar M, Gaffaroglu M, Vardi N, Koc M, Acet A. Protective effects of caffeic acid phenethyl ester (CAPE) on amikacin-induced nephrotoxicity in rats. Cell Biochem Funct. 2006 Jul–Aug; 24(4)363–367
   PubMedGoogle Scholar
• Horvath B, Marton Z, Halmosi R, Alexy T, Szapary L, Vekasi J, Biro Z, Habon T, Kesmarky G, Toth K. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin. Neuropharmacol. 2002; 25(1)37–42
   PubMed Web of Science ®Google Scholar
• Bhat VB, Madyastha KM. Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline. Biochem. Biophys. Res. Commun. 2001; 288(5)1212–1217
   PubMed Web of Science ®Google Scholar
• Freitas JP, Filipe P, Guerra-Rodrigo F. Potential antioxidative effects of pentoxifylline. CR Seances Soc. Biol. Fil. 1995; 189(3)401–405
   PubMedGoogle Scholar
• Freitas JP, Filipe PM. Pentoxifylline: A hydroxyl radical scavenger. Biol. Trace Elem. Res. 1995; 47(1–3)307–311
   PubMedGoogle Scholar
• de Campos T, Deree J, Martins JO, Loomis WH, Shenvi E, Putnam JG, Coimbra R. Pentoxifylline attenuates pulmonary inflammation and neutrophil activation in experimental acute pancreatitis. Pancreas. 2008 Jul; 37(1)42–49
   Google Scholar
• Wahhab MA, Nada SA, Arbid MS. Ochratoxicosis: Prevention of developmental toxicity by L-methionine in rats. J Applied Toxicol. 1999; 19: 7–12
   Google Scholar
• Humes HD. Aminoglycoside nephrotoxicity. Kidney Int. 1988; 33: 900–911
   PubMed Web of Science ®Google Scholar
• Nagai J, Tanaka H, Nakanishi N, Murakami T, Takano M. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol. 2001; 28: 337–344
   Google Scholar
• Krysztopik RJ, Matheson PJ, Spain DA, et al. Lazaroid and pentoxifylline suppress sepsis-induced increases in renal vascular resistance via altered arachidonic acid metabolism. J Surg Res. 2000; 93: 75–81
   Google Scholar
• Ambrus JL, Halpern J, Mahafzah M, et al. Platelet aggregation in septic shock: Effects of pentoxifylline. J Med. 1990; 21: 121–128
   Google Scholar
• Fink MP. Whither pentoxifylline?. Crit Care Med. 1999; 27: 19–20
   Google Scholar
• Ward A, Clissold SP. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987; 34: 50–97
   PubMed Web of Science ®Google Scholar
• Mandell GL. ARDS, neutrophils, and pentoxifylline. Am Rev Respir Dis. 1988; 138: 1103–1105
   PubMed Web of Science ®Google Scholar
• Berens KL, Langston JD, Wasan KM, et al. Influence of pentoxifylline and related analogues in endotoxemic renal failure. Circ Shock. 1991; 34: 344–348
   PubMedGoogle Scholar
• Kim YK, Yoo JH, Woo JS, et al. Effect of pentoxifylline on ischemic acute renal failure in rabbits. Ren Fail. 2001; 23: 757–772
   PubMed Web of Science ®Google Scholar
• Kim YK, Choi TR, Kwon CH, et al. Beneficial effect of pentoxifylline on cisplatin-induced acute renal failure in rabbits. Ren Fail. 2003; 25: 909–922
   PubMed Web of Science ®Google Scholar
• Savic V, Vlahovic P, Djordjevic V, et al. Nephroprotective effects of pentoxifylline in experimental myoglobinuric acute renal failure. Pathol Biol. (Paris). 2002; 50: 599–607
   PubMedGoogle Scholar
• Shifow AA, Naidu MU, Kumar KV, et al. Effect of pentoxifylline on cyclosporine-induced nephrotoxicity in rats. Indian J Exp Biol. 2000; 38: 347–352
   Google Scholar
• Boldt J, Muller M, Heesen M, al et. The effects of pentoxifylline on circulating adhesion molecules in critically ill patients with ARF treated by CVVH. Intensive Care Med. 1996; 22: 305–311
   PubMed Web of Science ®Google Scholar
• Boldt J, Brosch C, Piper SN, et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med. 2001; 29: 952–958
   PubMed Web of Science ®Google Scholar
• Dousa TP. Cyclic-3’, 5’-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int. 1999; 55: 29–62
   PubMed Web of Science ®Google Scholar
• Dousa TP. Signaling role of PDE isozymes in pathobiology of glomerular mesangial cells. Studies in vitro and in vivo. Cell Biochem. Biophys. 1998; 29: 19–34
   Google Scholar
• Dumaz N, Marais R. Protein kinase A blocks Raf-1 activity by stimulating 14–3-3 binding and blocking Raf-1 interaction with Ras. J. Biol. Chem. 2003; 278(29)819–823
   Google Scholar
• Chini CS, Chini EN, Williams JM, Matousovic K, Dousa TP. Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV. Kidney Int. 1994; 46: 28–36
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ, Dousa TP. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J. Clin. Invest. 1996; 98: 262–270
   PubMed Web of Science ®Google Scholar
• Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharide-induced tumour necrosis factor-a generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: Interaction with stimulants of adenylyl cyclase. Mol. Pharmacol. 1995; 48: 747–757
   PubMed Web of Science ®Google Scholar
• Klahr S, Morrissey J. Progression of chronic renal disease. Am. J. Kidney Dis. 2003; 41: S3–S7
   PubMed Web of Science ®Google Scholar
• Heystek HC, Thierry AC, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int. Immunol. 2003; 15: 827–835
   PubMedGoogle Scholar
• Shimizu E, Kobayashi Y, Oki Y, Kawasaki T, Yoshimi T, Nakamura H. OPC-13013, a cyclic nucleotide phosphodiesterase type III inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells. Life. Sci. 1999; 64: 2081–2088
   PubMed Web of Science ®Google Scholar
• Kohyama T, Liu X, Wen FQ, et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am. J. Respir. Cell. Mol. Biol. 2002; 26: 694–701
   PubMed Web of Science ®Google Scholar
• Meskini N, Nemoz G, Okyayuz-Baklouti I, Lagarde M, Prigent AF. Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem. Pharmacol. 1994; 47: 781–788
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Roehl A, Weissmann N, et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001; 281: L1361–L1368
   Google Scholar
• Ward A, Clissold SI. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs. 1987; 34: 50–97
   PubMed Web of Science ®Google Scholar
• Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J. Am. Soc. Nephrol. 2002; 13: 2916–2929
   PubMed Web of Science ®Google Scholar
• Tsai TJ, Lin RH, Chang CC, et al. Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron. 1995; 70: 91–100
   PubMed Web of Science ®Google Scholar
• Albornoz LE, Sanchez SB, Bandi JC, Canteros G, de las Heras M, Mastai RC. Pentoxifylline reduces nephrotoxicity associated with cyclosporine in the rat by its rheological properties. Transplant. 1997; 64: 1404–1407
   Google Scholar
• Chen YM, Chien CT, Hu-Tsai MI, et al. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int. 1999; 56: 932–943
   PubMed Web of Science ®Google Scholar
• Lin SL, Chen RH, Chen YM, Chiang WC, Tsai TJ, Hsieh BS. Pentoxifylline inhibits platelet-derived growth factor-stimulated cyclin D1 expression in mesangial cells by blocking Akt membrane translocation. Mol. Pharmacol. 2003; 64: 811–822
   PubMed Web of Science ®Google Scholar
• Chen YM, Chiang WC, Lin SL, Wu KD, Tsai TJ, Hsieh BS. Dual regulation of TNF-a-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle sells by NF-kB and AP-1: Modulation by type III phosphodiesterase inhibition. J. Pharmacol. Exp. Ther. 2004; 309: 978–986
   Google Scholar
• Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ. Pentoxifylline suppresses renal tumour necrosis factor-a and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol. Dial. Transplant. 2004; 19: 1106–1115
   Google Scholar
• Navarro JF, Mora C, Rivero A, et al. Urinary protein excretion and serum tumour necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am. J. Kidney. Dis. 1999; 33: 458–463
   PubMed Web of Science ®Google Scholar
• Navarro JF, Mora C, Muros M, Maca M, Garca J. Effects of pentoxifylline administration on urinary N-acetyl-b- glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective randomized study. Am. J. Kidney Dis. 2003; 42: 264–270
   PubMedGoogle Scholar
• Ducloux D, Bresson-Vautrin C, Chalopin JM. Use of pentoxifylline in membranous nephropathy. Lancet. 2001; 357: 1672–1673
   PubMed Web of Science ®Google Scholar
• Segal R, Dayan M, Zinger H, Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNF-a monoclonal antibody and by pentoxifylline. Lupus. 2001; 10: 23–31
   PubMed Web of Science ®Google Scholar